RxDoctor Payments Data

Musaddiq Tariq, MD

Psychiatry · Hackensack, NJNPI 1326465436

Payments from drug & device makers

$751in general payments, 2019–2025

Across 33 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$183
  • Alkermes, Inc.$179
  • Johnson & Johnson$132
  • Jazz Pharmaceuticals Inc.$98
  • Otsuka America Pharmaceutical, Inc.$72
  • AbbVie$24
  • plus $62 from 3 others

What the payments were for

  • Food & beverage$751100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$751 in reported general payments places this provider in the 70th percentile of 1,119 psychiatry providers in New Jersey.

See all psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$17,332
Medicare patients
51
Services billed
142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine11$79,640
Invega SustennaPaliperidone Palmitate11$36,496
Aripiprazole14$2,999
Olanzapine42$1,315
Clozapine13$1,173
Quetiapine Fumarate49$544
Divalproex Sodium17$531
Haloperidol20$530
Duloxetine Hcl26$495
Hydroxyzine Pamoate43$398
Venlafaxine Hcl ErVenlafaxine Hcl11$346
Bupropion XlBupropion Hcl17$287
Hydroxyzine Hcl15$239
Prazosin Hcl15$197
Sertraline Hcl27$176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$21$79,64011 claims
Johnson & JohnsonInvega Sustenna$132$36,49611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,119 psychiatry providers in New Jersey.

Other psychiatry in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →